Website: N/A
Stock Symbol: NASDAQ: IDRA
Market Value: N/A (in millions)
We are engaged in the discovery and development of DNA- and RNA-based drug
candidates targeted to Toll-Like Receptors, or TLRs, to treat infectious
diseases, autoimmune diseases, cancer, and asthma and allergies, and for use as
vaccine adjuvants. Drug candidates are compounds that we are developing and have
not been approved for any commercial use. TLRs are specific receptors present in
immune system cells that recognize the DNA or RNA of pathogens such as bacteria
or viruses and initiate an immune response. Relying on our expertise in DNA and
RNA chemistry, we have designed and created proprietary TLR agonists and
antagonists to modulate immune responses. A TLR agonist is a compound that
stimulates an immune response through the targeted TLR. A TLR antagonist is a
compound that blocks activation of an immune response through the targeted TLR.
Our business strategy is to advance applications of our TLR-targeted compounds
in multiple disease areas simultaneously.